We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder.
GLEN ALLEN, Va., July 23, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (βAdialβ or the βCompanyβ), a clinical-stage biopharmaceutical company focused on developing...
GLEN ALLEN, Va., June 20, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (βAdialβ or the βCompanyβ), a clinical-stage biopharmaceutical company focused on developing...
Study intended to optimize design elements needed for the upcoming US Pivotal Phase 3 studiesand support ongoing partnership discussions Topline results expected in early Q4 2024 GLEN ALLEN, Va...
GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (βAdialβ or the βCompanyβ), a clinical-stage biopharmaceutical company focused on developing...
GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (βAdialβ or the βCompanyβ), a clinical-stage biopharmaceutical company focused on developing...
GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (βAdialβ or the βCompanyβ), a clinical-stage biopharmaceutical company focused on developing...
GLEN ALLEN, Va., April 10, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (βAdialβ or the βCompanyβ), a clinical-stage biopharmaceutical company focused on developing...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.13 | 11.8181818182 | 1.1 | 3 | 1.04 | 68495 | 1.09567427 | CS |
4 | 0.08 | 6.95652173913 | 1.15 | 3 | 1 | 55685 | 1.09452068 | CS |
12 | -0.46 | -27.2189349112 | 1.69 | 3 | 1 | 154909 | 1.34846819 | CS |
26 | -0.11 | -8.20895522388 | 1.34 | 4.12 | 0.765 | 3323230 | 2.2793962 | CS |
52 | -5.495 | -81.7100371747 | 6.725 | 8.875 | 0.765 | 1720385 | 2.36481159 | CS |
156 | -58.02 | -97.9240506329 | 59.25 | 127 | 0.765 | 987358 | 11.41421456 | CS |
260 | -48.27 | -97.5151515152 | 49.5 | 127 | 0.765 | 880695 | 27.67964291 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions